Pyxis Oncology, Inc. (PYXS) scores 30 out of 100 on boothcheck's 11-model valuation framework. Verdict: Bad The estimated fair value is 0.01, representing a 99% premium to fair value. Quantitative score: 41/100. Qualitative score: 40/100.
Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.